News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
165 Results
Type
Article (49)
Company Profile (1)
Press Release (115)
Section
Business (64)
Deals (20)
Drug Development (15)
Job Trends (5)
News (75)
Policy (1)
Tag
Alliances (14)
Bankruptcy (1)
Best Places to Work (3)
Biotechnology (1)
CAR-T (1)
Cell therapy (1)
Clinical research (4)
Collaboration (2)
COVID-19 (2)
CRISPR (2)
C-suite (1)
Data (6)
Diagnostics (1)
Earnings (14)
Events (35)
Gene editing (12)
Gene therapy (4)
Healthcare (9)
Infectious disease (2)
Inflammatory bowel disease (1)
IPO (23)
Layoffs (4)
Multiple sclerosis (1)
Neuroscience (1)
NextGen: Class of 2026 (17)
Non-profit (1)
People (18)
Phase 1 (2)
Phase 2 (3)
Pipeline (5)
Preclinical (7)
Regulatory (1)
Startups (5)
The Weekly (1)
Vaccines (1)
Date
Today (1)
Last 7 days (2)
Last 30 days (3)
Last 365 days (18)
2026 (4)
2025 (17)
2024 (45)
2023 (17)
2022 (40)
2021 (25)
2020 (10)
2019 (1)
2018 (3)
2017 (1)
2016 (2)
Location
Asia (3)
Australia (1)
California (29)
Canada (2)
Europe (6)
Massachusetts (1)
Northern California (24)
United States (30)
165 Results for "metagenomi".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Metagenomi Chops 25% of Workforce, CEO To Advance Hemophilia A Program
The strategic initiative will extend Metagenomi’s cash runway into the fourth quarter of 2027. That same year, the company expects to generate initial Phase I data for its lead asset MGX-001 in hemophilia A.
November 12, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
January 13, 2026
·
7 min read
Press Releases
Metagenomi to Present at Jefferies 2025 Global Healthcare Conference in London
November 18, 2025
·
3 min read
Press Releases
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
December 2, 2025
·
4 min read
Press Releases
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
November 11, 2025
·
11 min read
Press Releases
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
November 11, 2025
·
7 min read
Press Releases
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
August 12, 2025
·
5 min read
Press Releases
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
August 13, 2025
·
8 min read
Press Releases
Metagenomi to Present at Upcoming Scientific Meetings
May 2, 2025
·
4 min read
IPO
Metagenomi CSO Steps Down Shortly After IPO, Moderna Exit
Following a disappointing IPO and the loss of Moderna’s gene editing contract, Metagenomi’s Chief Scientific Officer Luis Borges is departing the biotech.
July 15, 2024
·
2 min read
·
Tristan Manalac
1 of 17
Next
